Navigation Links
Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert

STEWARTVILLE, Minn., Nov. 5 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (Nasdaq: ROCM) today announced operating results for its fourth quarter and year ended September 30, 2009.

The Company reported sales of $9,009,000 for the current quarter compared to $9,512,000 for the fourth quarter of last year. The Company reported a quarterly net loss of $229,000 or ($.02) per diluted share compared to net income of $342,000 or $.03 per diluted share for the fourth quarter of last year.

The approximate 5% decrease in sales (.6% decrease on a constant currency basis) resulted from a 2% increase in Rochester Medical Branded Sales (10% increase on a constant currency basis), offset by a 20% decrease in Private Label Sales (20% decrease on a constant currency basis). Constant currency basis assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations. In the fourth quarter of 2009 the U.S. dollar was significantly stronger versus the pound sterling, thus negatively affecting Rochester Medical Branded Sales levels in translated U.S. dollars given the significant volume of branded product sales in the United Kingdom.

Net income adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income" for the current quarter was $95,000 or $.01 per diluted share compared to Non-GAAP Net Income of $658,000 or $.05 per diluted share for the fourth quarter of last year. The decrease for the current quarter on a Non-GAAP basis is primarily attributable to the impact of exchange rate variation and increased investment in Sales and Marketing programs.

For the fiscal year ended September 30, 2009, the Company reported sales of $34,799,000 compared to sales of $35,192,000 for the previous year. It reported net income for the year of $109,000 or $.01 per diluted share compared to net income of $759,000 or $.06 per diluted share for the previous year. The approximate 1% decrease in annual sales (7% increase on a constancy currency basis) resulted from a 2% decrease in Rochester Medical Branded Sales (10% increase on a constant currency basis) partially offset by a 2% increase in Private Label Sales (2% increase on a constant currency basis).

Non-GAAP Net Income for the current year was $865,000 or $.07 per diluted share compared to Non-GAAP Net Income of $2,174,000 or $.17 per diluted share for the previous year. The decrease for the current year on a Non-GAAP basis is primarily due to the impact of exchange rate variation and increased investment in Sales and Marketing. It is also due to a tax benefit of $654,000 taken in the third quarter of last year and higher interest income in the prior year.

Rochester Medical also announced that a device reimbursement code has been issued this week by Medicare covering the Company's FemSoft Insert, which is a soft disposable device used to manage female stress urinary incontinence. The Company believes the availability of Medicare reimbursement, which commences in 2010, will help this unique device become an economically accessible and often preferred solution for incontinent women in the U.S.

Commenting on today's announcements, Rochester Medical's CEO and President Anthony Conway said, "First I must say that I am delighted with the Medicare reimbursement approval for the FemSoft Insert. This unique technology has the potential to help millions of women deal with the difficulties of incontinence with comfort, dignity, and grace. Rochester Medical is putting the appropriate plans in place to ensure that clinicians and women throughout the country have access to this excellent choice.

"Regarding the quarterly results, I think it is particularly important to highlight our progress in the U.S. and U.K., the areas of our direct sales and marketing focus. Combined fourth quarter sales of all Rochester Medical Branded products in those markets were up a solid 15% on a constant currency basis compared to the same period of the prior year. In those same combined markets on a constant currency basis, sales of Intermittent Catheters rose an impressive 46%, and Foley Catheter sales were up strongly with a 68% increase. These two product lines are our current growth drivers and, along with the FemSoft Insert, are expected to be the primary growth drivers in 2010 and beyond. The 20% drop in Private Label Sales is strictly due to timing of orders which causes the quarterly up and down fluctuations." To that point Conway noted Private Label Sales were up 42% in the third quarter and for the year were up 2%.

Conway continued, "We introduced the StrataSI(TM) and StrataNF(TM) Foley Catheters this quarter and we are extremely pleased with the initial reception. I believe that the comfortable softness and gentle feel of these all silicone catheters along with the infection prevention characteristics provide a clearly superior choice over latex catheters for all patients. Latex catheters currently make up 90% of the U.S. Foley catheter market.

"Looking ahead, given the new Strata product line, the recently introduced MAGIC3(TM) Intermittent Catheter line, the just announced National Healthcare System reimbursement for the FemSoft female incontinence insert in the U.K., and the Medicare final reimbursement approval announced today for FemSoft in the U.S., 2010 promises to be a very interesting and active year for Rochester Medical."

Rochester Medical has provided Non-GAAP Net Income in addition to earnings calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Similarly, constant currency represents reported sales with the cost/benefit of currency movements removed. Management uses the measure to understand the growth of the business on a constant dollar basis, as fluctuations in exchange rates can distort the underlying growth of the business both positively and negatively. While we recognize that foreign exchange volatility is a reality for a global company, we routinely review our company performance on a constant dollar basis, and we believe this also allows our shareholders to understand better our Company's growth trends.

Non-GAAP Net Income and constant currency are not measures of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income and constant currency are not comparable to information provided by other companies. Non-GAAP Net Income and constant currency have limitations as analytical tools and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of Net Income and Non-GAAP Net Income, and reconciliations of sales under GAAP and sales on a constant currency basis, are presented at the end of this press release.

This press release contains "forward-looking statements" that are based on currently available information, operating plans and management's expectations about future events and trends. They inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2008 and subsequent reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

The Company will hold a quarterly conference call to discuss its earnings report. The call will begin at 3:30 p.m. central time (4:30 p.m. eastern time).

This call is being webcast by Thomson/CCBN and can be accessed at Rochester Medical's website at To listen live to the conference call via telephone, call:

    Domestic:         888.680.0893
    International:    617.213.4859
    Pass code:        64235793
    Pre Registration:
    Replay will be available for seven days at
     or via telephone at:
    Domestic:         888-286-8010
    International:    617-801-6888
    Pass code:        31548516

Individual investors can listen to the call at, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company markets under its own Rochester Medical® brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at

    Reconciliation of Reported GAAP Revenue to Non-GAAP Revenue in Constant
    For the Three and Twelve months ended
    September 30, 2009

                                      (unaudited)              (unaudited)
                                  Three months ended       Twelve months ended
                                     September 30,            September 30,
                                     -------------            -------------
                                   2009        2008         2009         2008
                                   ----        ----         ----         ----

    GAAP Sales as Reported   $9,009,299  $9,512,191  $34,798,829  $35,191,949
                             ==========  ==========  ===========  ===========
          Exchange rate
           as Reported             1.64        1.89         1.55         1.97
                                   ====        ====         ====         ====

    Constant Currency Sales  $9,009,299  $9,062,879  $34,798,829  $32,440,497
                             ==========  ==========  ===========  ===========
      (1) Exchange rate
           used for
           Purposes                1.64        1.64         1.55         1.55
                                   ====        ====         ====         ====

    Net Effect of Constant
     Currency Illustration           $-   $(449,312)          $-  $(2,751,452)
                                     ==   =========           ==  ===========

    (1)  For illustrative purposes constant currency translates prior period
         foreign sales at current exchange rates.
         For Rochester Medical Corporation this is the conversion rate of
         pound sterling to US dollars.  The rate represents the average
         exchange rate for the respective three or twelve month period.

    Reconciliation of Reported GAAP Net Income to Non-GAAP Net Income
    For the Three and Twelve months ended
    September 30, 2009 and 2008

                                      (unaudited)            (unaudited)
                                  Three months ended    Twelve months ended
                                     September 30,          September 30,
                                     -------------          -------------
                                    2009        2008       2009        2008
                                    ----        ----       ----        ----
    GAAP Net Income
     (Loss) as Reported        $(229,000)   $342,000   $109,000    $759,000
                               =========    ========   ========    ========

    Diluted Earnings (Loss)
     Per Share as Reported        $(0.02)      $0.03      $0.01       $0.06
                                  ======       =====      =====       =====

    Adjustments for non-
     recurring unusual
       Settlement income
        after taxes (1)                -           -   (637,000)          -
                                     ---         ---   --------         ---
    Subtotal                           -           -   (637,000)          -

    Adjustments for
     recurring non-cash
        amortization (2)         129,000     129,000    515,000     515,000
       FAS 123R compensation
        expense (3)              195,000     187,000    878,000     900,000
                                 -------     -------    -------     -------
    Subtotal                     324,000     316,000  1,393,000   1,415,000
                                 -------     -------  ---------   ---------

    Non-GAAP Net Income          $95,000    $658,000   $865,000  $2,174,000
                                 =======    ========   ========  ==========

    Non-GAAP Diluted EPS           $0.01       $0.05      $0.07       $0.17
                                   =====       =====      =====       =====

    Weighted Average Shares -
     Diluted                  12,702,241  12,587,427 12,639,853  12,577,337

    (1)  Settlement income received January 15, 2009 from Covidien Ltd. of
         $1,000,000, $637,000 after taxes of $363,000. This adjustment reduces
         net income for amounts received net of taxes paid in connection with
         one-time settlement of certain litigation. These amounts were
         recorded in Other Income in the Statement of Operations for the
         twelve months ended September 30, 2009.

    (2)  Amortization of the intangibles acquired in June 2006 asset
         acquisition from Coloplast AS and Mentor Corporation. Management
         believes these assets are appreciating. This adjustment adds back
         amortization expense for the three and twelve months ended September
         30, 2009 and 2008 related to certain intangibles. The gross amount of
         amortization is $163,000 per quarter after taxes of $34,000 for a net
         amount of $129,000.

    (3)  Compensation expense mandated by SFAS 123R.  This adjustment adds
         back the compensation expense recorded for stock options granted to
         employees and directors that vested during the three and twelve
         months ended September 30, 2009 and 2008. The gross amount of
         compensation expense for the three months ended September 30, 2009
         and 2008 is $295,000 and $283,000 net of taxes of $100,000 and
         $96,000 for net amounts of $195,000 and $187,000, respectively. The
         gross amount of compensation expense for the twelve months ended
         September 30, 2009 and 2008 is $1,330,000 and $1,364,000 net of taxes
         of $452,000 and $464,000 for net amounts of $878,000 and $900,000,

    Rochester Medical Corporation
    Press Release - F09 Fourth Quarter

                   Condensed Balance Sheets

                                September 30, September 30,
                                        2009          2008
                                        ----          ----


      Current Assets
        Cash and equivalents      $6,365,584    $8,508,000
        Marketable securities     29,896,740    28,493,648
        Accounts receivable        6,418,656     6,009,023
        Inventories                9,710,234     8,745,873
        Prepaid expenses and
         other assets              1,076,183     1,110,291
        Deferred income tax        1,153,964     1,143,931
                                   ---------     ---------

          Total current assets    54,621,361    54,010,766

      Property and equipment,
       net                         9,683,808     9,883,329
      Deferred income tax            768,874       831,299
      Patents, net                   224,815       227,358
      Intangible assets, net       6,017,944     6,860,213
      Goodwill                     4,648,165     5,169,661
                                   ---------     ---------

      Total Assets               $75,964,967   $76,982,626
                                 ===========   ===========

         Liabilities and
       Stockholders' Equity

      Current liabilities:
        Accounts payable          $1,755,472    $2,127,470
        Accrued expenses           1,527,352     1,170,654
        Short-term debt            2,786,622     1,940,292
                                   ---------     ---------

          Total current
           liabilities             6,069,446     5,238,416

      Long-term liabilities
        Other long-term
         liabilities                  55,889       239,496
        Long-term debt             1,019,735     3,806,185
                                   ---------     ---------

          Total long-term
           liabilities             1,075,624     4,045,681

      Stockholders' equity        68,819,897    67,698,529
                                  ----------    ----------

      Total Liabilities and
       Stockholders' Equity      $75,964,967   $76,982,626
                                 ===========   ===========

    Rochester Medical Corporation
    Press Release - F09 Fourth Quarter

                        Summary Statements Of Operations

                                   (unaudited)              (unaudited)
                               Three months ended       Twelve months ended
                                  September 30,            September 30,
                                  -------------            -------------
                                2009        2008         2009         2008
                                ----        ----         ----         ----

    Sales                 $9,009,299  $9,512,191  $34,798,829  $35,191,949

    Cost of sales          4,706,579   4,889,789   17,973,314   18,483,985
                           ---------   ---------   ----------   ----------

    Gross profit           4,302,720   4,622,402   16,825,515   16,707,964
      Gross profit %              48%         49%          48%          47%

    Costs and expense:
       Marketing and
        selling            2,771,460   2,544,014   10,327,396    9,498,596
       Research and
        development          272,084     308,913    1,241,095    1,044,205
       General and
        administrative     1,432,610   1,447,707    6,006,906    6,658,002
                           ---------   ---------    ---------    ---------

    Total operating
     expenses              4,476,154   4,300,634   17,575,397   17,200,803
                           ---------   ---------   ----------   ----------

    (Loss) Income from
     operations             (173,434)    321,768     (749,882)    (492,839)

    Other income (expense)

       Interest income        41,705     197,997      283,195    1,239,689
       Interest expense      (40,627)    (82,674)    (259,341)    (477,560)
       Other income
        (expense)                  -     (88,642)   1,200,442      (88,642)
                                 ---     -------    ---------      -------

    Net income (loss)
     before income taxes    (172,356)    348,449      474,414      180,648

    Income tax
     expense (benefit)        56,899       6,291      365,742     (578,455)
                              ------       -----      -------     --------

    Net income (loss)      $(229,255)   $342,158     $108,672     $759,103
                           =========    ========     ========     ========

    Earnings (loss) per
     common share - Basic     $(0.02)      $0.03        $0.01        $0.06
                              ======       =====        =====        =====

    Earnings (loss) per
     common share -
     Diluted                  $(0.02)      $0.03        $0.01        $0.06
                              ======       =====        =====        =====

    Weighted Average
       Basic              12,091,856  11,878,956   12,045,313   11,815,904
                          ==========  ==========   ==========   ==========

    Weighted Average
       Diluted            12,091,856  12,587,427   12,639,853   12,577,337
                          ==========  ==========   ==========   ==========

SOURCE Rochester Medical Corporation

SOURCE Rochester Medical Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
2. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. Symmetry Medical Reports Third Quarter 2009 Financial Results
5. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
6. Sarnova Acquires Metropolitan Medical to Expand Portfolio of Specialty Health Care Products
7. ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference
8. CMS Admits New Surety Bond and Accreditation Requirement for Home Medical Equipment Suppliers Creating Patient Access Issues
9. AACE Issues New Medical Guidelines for Proper and Ethical Use of Growth Hormone
10. Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits"
11. Medical Imaging Solutions Firm Dicom Solutions Ranks No. 109 on the Inc. 500
Post Your Comments:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... 12, 2017 , ... On Saturday, October 21, the Health & Wellness Center ... to raise money for the American Heart Association Heart Walk. Teams of up to ... together to keep their treadmills moving for 5 hours. Treadmills will start at 7:00 ...
(Date:10/12/2017)... ... 12, 2017 , ... In the United States, single-family home ... states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average is ... low property-tax rates, which contributes to the relatively lower cost of living in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Pepper Flow promotional review platform at the Promotional Review Committee Compliance and ... help marketers streamline the medical, legal, and regulatory review (MLR) process – ...
Breaking Medicine News(10 mins):